内部人交易记录
董事尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Browse the detailed record of transactions filed by Gryska David W, 董事. Insider active across 6 companies, notably Seagen Inc.. In total, 20 reports have been logged. Breakdown: 2 buys · 1 sell. Total volume traded: €986k. History available since 14 May 2021. The latest transaction was disclosed on 5 December 2024 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Gryska David W
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报20 总计
5,940 股Common StockSEC:0001202335-26-000003:0
4,666 股Common SharesSEC:0001193125-26-271163:0
2,500 股@ US$7.1747.5% 占其流量Common SharesSEC:0000950170-24-133724:0
3,500 股@ US$5.9852.5% 占其流量Common SharesSEC:0000950170-24-100668:0
49,003 股@ US$229.0087.2% 占其流量Common StockSEC:0000950170-23-070865:0
148,514 股@ US$1.01100.0% 占其流量Common StockSEC:0001209191-23-044284:0
13,851 股0Common SharesSEC:0000899243-23-016426:0
2,044 股0Common StockSEC:0001203311-23-000063:0
8,750 股@ US$36.702.5% 占其流量Common StockSEC:0001203311-23-000014:0
11,495 股@ US$15.25100.0% 占其流量Common StockSEC:0001209191-22-058176:0
7,500 股@ US$129.0968.0% 占其流量Common StockSEC:0001203311-22-000059:0
6,245 股0Common StockSEC:0001209191-22-036389:0
1,503 股0Common StockSEC:0000899243-22-018466:0
1,794 股@ US$20.060.3% 占其流量Common StockSEC:0001203311-22-000021:0
1,100 股@ US$20.060.2% 占其流量Common StockSEC:0001203311-22-000013:0
850 股@ US$20.060.1% 占其流量Common StockSEC:0001203311-22-000008:0
4,500 股@ US$20.060.7% 占其流量Common StockSEC:0000899243-22-002477:0
1,750 股0Common StockSEC:0001209191-21-042040:0
1,402 股0Common StockSEC:0001203311-21-000035:0
2,610 股Common StockSEC:0001209191-16-090535:0
About Gryska David W
GRYSKA DAVID W is Administrateur. He appears in 19 filings in total, and in the sampled recent filings between 2016-01-08 and 2026-06-15, the reported amounts are EUR 35,875 in buys and EUR 11,427,886 in sells, with the transaction nature mainly shown as Attribution. His listed companies are Seagen Inc., Mind Medicine (MindMed) Inc., Aerie Pharmaceuticals INC, Definium Therapeutics, Inc., Forte Biosciences, Inc., and INCYTE CORP.